Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Trump escalates attacks on prosecutors, says Democrats run ‘a Gestapo administration’

Top RNC lawyer resigns after rift grows with Trump

Divided Trump campaign weighs joining TikTok, the app he tried to ban

How Pope Francis opened the Vatican to transgender sex workers

Israeli cabinet votes to shut Al Jazeera’s Israel operations; cease-fire talks ongoing

Residents accuse Israeli forces of executions during West Bank raid

In photos: The 150th running of the Kentucky Derby

University of Michigan graduation disrupted by protesters

Protesters clash with law enforcement at U-Va.

Carolyn Hax: Working for a celebrity has this employee feeling ‘small’

Ask Amy: I live with my boyfriend – and his sister and her family

Miss Manners: Is it inappropriate to reach out to old girlfriends?

The new cure-all for vacation excess: the IV drip 

What’s the best bus to New York? We tested 5 for comfort and value.

You asked: Do I need a passport for my cruise?

Strangers help Sesame Street puppeteer after heirloom necklace was stolen

Teen grabs wheel when driver passes out and school bus veers into traffic

Cat climbed into Amazon return box, found alive 630 miles away

A frank look at hot dog prices at MLB ballparks

Sloppy first inning dooms the Nationals in a 6-3 loss to the Blue Jays

In a pinch, the Nationals finally find some offense

After years of delay, Boeing to try again with Starliner space capsule

Google’s empire is massive. A judge will soon rule if it’s a monopoly.

The Post endorses April McClain Delaney and Tom Royals for Maryland’s 6th District

On Press Freedom Day, little to celebrate for Hong Kong’s journalists

Young Georgians want to be part of Europe. Their government is in the way.

The New York Times, alone in its outrage over access to Biden

The ‘Access Hollywood’ video cemented Trump’s air of invincibility

Stephen A. Smith would like even more of your attention

The Food and Drug Administration approved a second version of a groundbreaking treatment Wednesday that genetically alters patients' cells to attack cancer — this time, to fight aggressive non-Hodgkin lymphoma.

The treatment is for adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment, such as chemotherapy and bone-marrow transplants. The group numbers about 7,500 patients a year in the United States.

The one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently <a href="https://www.washingtonpost.com/news/wonk/wp/2017/08/29/gileads-11-9-billion-purchase-of-a-groundbreaking-cancer-therapy-could-drag-it-into-a-new-debate-on-prices/?utm_term=.6f6533b0d38a">was bought</a> by Gilead Sciences for $11.9 billion. Kite announced Wednesday that the treatment's brand name will be Yescarta and its price will be $373,000.

In late August, the FDA <a href="https://www.washingtonpost.com/news/to-your-health/wp/2017/08/30/fda-approves-first-of-its-kind-living-drug-for-childhood-leukemia/?utm_term=.1291e4fc4c8b">cleared</a> the first CAR T-cell therapy, which is designed for children and young adults whose leukemia doesn't respond to standard treatments. About 600 patients in the United States fall into that category every year. Kymriah, which costs $475,000, is manufactured by Novartis.

Biotech analysts had expected the Kite price to be lower than Kymriah's, in part because the number of eligible patients is larger and the response rates are lower. Even so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.

The FDA approval is the latest step forward for the fast-moving field of immunotherapy, which aims to bolster the immune system to attack malignancies. CAR T-cell therapies are among several approaches, along with treatments called <a href="https://www.washingtonpost.com/national/health-science/cancer-fighting-power-couple-tackles-mysteries-of-the-immune-system/2017/09/29/db52e514-810e-11e7-ab27-1a21a8e006ab_story.html?utm_term=.b07d069198fd">checkpoint inhibitors</a> and cancer vaccines, but they have recently grabbed much of the attention. Dozens of other companies also are working on them.

“Today, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,” FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates “the continued momentum of this promising new area of medicine.”

A CAR T-cell therapy involves a complicated and customized procedure in which T cells — sometimes called the foot soldiers of the immune system — are removed from the patient. They are sent to a special lab and genetically modified  to target a protein on the surface of the patient's cancer cells. Once the modified cells are returned to the patient, their numbers expand exponentially as they become an army of cancer fighters.

In 2015, Marie Miceli was diagnosed with non-Hodgkin lymphoma at Siteman Cancer Center in St. Louis, which is jointly owned by Barnes-Jewish Hospital and Washington University School of Medicine. She received chemo and underwent a bone-marrow transplant. Neither worked.

“The doctors were saying, 'Go see an attorney and get your life in order,' " the 64-year-old Realtor recalled. Then they offered her a slot in Kite's clinical trial, a last-resort effort. “I could feel it when they put those T cells back in,” she said. “It was the craziest feeling in the world.” When she was checked a month later, she said, her cancer was gone. It hasn't returned.

Kite's “vein-to-vein” turnaround period — from cell extraction to reinfusion — is about 17 days, according to Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa and co-leader of the Kite trial.

The FDA said the safety and efficacy of Yescarta were established in a multi-center trial of more than 100 adults with large B-cell lymphoma. An independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer. Kite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.

“This is not just an incremental benefit,” said David Chang, Kite's chief medical officer. “It raises the potential that a cure can be possible.” Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.

Locke said about 13 percent of patients in the trial had a <a href="https://www.washingtonpost.com/news/to-your-health/wp/2017/10/12/cancer-researchers-learn-more-about-toxic-side-effects-of-new-treatments/?utm_term=.ec573da72c7a">severe side effect</a> known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms. Twenty-eight percent had neurological “events,” such as severe confusion; three patients died of complications caused by the treatment.

“These are patients who knew they were out of options,” he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.

Because of the side effects, the treatment will carry a boxed warning, the FDA's most serious. In addition, the agency is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults. This type of cancer begins in the immune system and can be fast- or slow-growing, the FDA noted.

Kite's CAR T-cell product was developed years ago at the National Cancer Institute by pioneering scientist Steven Rosenberg and licensed to the company for commercialization.

Armin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is “just the first step” and that researchers are working to make it safer and more effective. He said the therapy already has been life-changing for many of his patients — and for him.

“There's nothing worse than telling patients, 'I'm sorry, we are done here, we don't have anything else to offer,' " he said.

<a href="https://www.washingtonpost.com/national/health-science/fda-advisers-urge-approval-for-first-gene-therapy-for-inherited-disease/2017/10/12/d6f4d432-aec2-11e7-9e58-e6288544af98_story.html?utm_term=.5d963b67fd8a">FDA advisers urge approval for first gene therapy for inherited disease</a>

<a href="https://www.washingtonpost.com/news/to-your-health/wp/2017/10/03/breast-cancer-death-rate-drops-almost-40-percent-saving-32200-lives-study-says/?utm_term=.08588eae75b2">Breast-cancer death rate drops almost 40 percent, saving 322,000 lives, study says</a>

<a href="https://www.washingtonpost.com/news/to-your-health/wp/2017/07/26/these-experimental-treatments-target-brain-cancer-like-john-mccains/?utm_term=.09786b4b4698">These experimental treatments target brain cancer like John McCain's</a>

Part of Wall Street Journal team that won the 1997 Pulitzer Prize for national reporting on AIDS 

Syracuse University, BS in journalism

Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor. 

Laurie McGinley

The Washington Post

Health Care

Medical Mysteries

Science

Well+Being

Health

prism://prism.query/site,/health&limit=20

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.